Govaerts, C.W.; Kramer, M.C.A.; Bosma, I.; Kruyt, F.A.E.; Bensch, F.; van Dijk, J.M.C.; Jalving, M.; van der Hoorn, A.
Incidence and Clinical Features of Pseudoprogression in Brain Metastases After Immune-Checkpoint Inhibitor Therapy: A Retrospective Study. Cancers 2025, 17, 2425.
https://doi.org/10.3390/cancers17152425
AMA Style
Govaerts CW, Kramer MCA, Bosma I, Kruyt FAE, Bensch F, van Dijk JMC, Jalving M, van der Hoorn A.
Incidence and Clinical Features of Pseudoprogression in Brain Metastases After Immune-Checkpoint Inhibitor Therapy: A Retrospective Study. Cancers. 2025; 17(15):2425.
https://doi.org/10.3390/cancers17152425
Chicago/Turabian Style
Govaerts, Chris W., Miranda C. A. Kramer, Ingeborg Bosma, Frank A. E. Kruyt, Frederike Bensch, J. Marc C. van Dijk, Mathilde Jalving, and Anouk van der Hoorn.
2025. "Incidence and Clinical Features of Pseudoprogression in Brain Metastases After Immune-Checkpoint Inhibitor Therapy: A Retrospective Study" Cancers 17, no. 15: 2425.
https://doi.org/10.3390/cancers17152425
APA Style
Govaerts, C. W., Kramer, M. C. A., Bosma, I., Kruyt, F. A. E., Bensch, F., van Dijk, J. M. C., Jalving, M., & van der Hoorn, A.
(2025). Incidence and Clinical Features of Pseudoprogression in Brain Metastases After Immune-Checkpoint Inhibitor Therapy: A Retrospective Study. Cancers, 17(15), 2425.
https://doi.org/10.3390/cancers17152425
